In recent years, the market for weight-loss medications has seen robust growth, driven by increasing interest from clinicians and patients alike. Alongside diet and exercise, several classes of drugs have gained traction as useful tools for achieving sustained weight loss, especially in people with obesity or overweight associated with metabolic risk factors. Anti-obesity medications represent a valuable component of multidisciplinary obesity management, requiring a personalized approach based on individual risk, comorbidities, and patient preferences. The research horizon remains promising: advances in new pharmacological targets, more practical formulations, and greater integration with non-pharmacological interventions could offer increasingly effective and safe solutions in the future.
What they do and how they are classified
GLP-1 receptor agonists (glucagon-like peptide-1): injectable drugs, often administered weekly. They act by modulating appetite, slowing gastric emptying, and improving insulin function. Notable examples: semaglutide (Ozempic for diabetes, Wegovy for weight loss) and liraglutide (Saxenda). Common results in trials: significant weight loss versus placebo, with potential benefits on glycemia, blood pressure, and lipid profile. SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors): primarily used for type 2 diabetes, they have shown modestly greater weight loss versus placebo and metabolic benefits. Some studies suggest reduced caloric intake and metabolic changes, but off-label use for weight loss requires caution and supervision. PPAR gamma receptor agonists or metabolic modulators: experimental and in advanced stages of study, aiming to modulate lipid metabolism and lean mass, with efficacy and long-term safety still uncertain.Combination drugs and multi-target therapies: approaches combining actions on appetite, energy metabolism, and intestinal absorption. Some early studies show promise, but long-term safety remains a priority in evaluation.
Common side effects and safety considerations
Gastrointestinal: nausea, vomiting, diarrhea, or constipation are among the most frequent adverse events, particularly with GLP-1 agonists.Lipids and liver function: some drugs can alter cholesterol levels or cause transient changes in liver enzymes; periodic monitoring is often recommended. Endocrine and metabolic: variations in appetite and body weight, and in some cases signs of dehydration or orthostatic hypotension. Long-term safety: sustained weight loss should be weighed against rebound risk, tolerance, and potential adverse effects not yet fully described by available data.
What to ask your doctor before starting
What is a realistic weight-loss goal for me (percentage or kilograms over a defined period)? What are the potential side effects and how should they be monitored? Are there contraindications related to existing health conditions (hypertension, diabetes, kidney or liver disease, pancreatitis, thyroid problems)?What is the accompanying non-pharmacological plan (nutrition, physical activity, behavioral support) that accompanies the therapy? What periodic checks are needed (follow-up visits, laboratory tests, blood pressure monitoring)?Note: this text is for informational purposes. Always consult a medical professional for a personalized assessment and to follow a therapy plan tailored to your needs, adhering to the instructions of your treating physician.